Healthcare technology company R1 RCM Inc. (RCM) entered into a definitive merger agreement on August 1, 2024, to be acquired by private equity firms TowerBrook Capital Partners and Clayton, Dubilier & Rice (CD&R), in an all-cash deal valued at $8.9 billion, including debt.
Under the terms of the agreement, TowerBrook and CD&R will acquire all the outstanding common stock of R1 RCM for $14.30 per share, representing a premium of 11.02% from the stock’s last close.